Abstract
Clostridium difficile infection (CDI) has become a significant threat to public health. Although broad-spectrum antibiotic therapy is the primary treatment option for CDI., its use has evident limitations. Probiotics have been proved to be effective in the treatment of CDI and are a promising therapeutic option for CDI. In this study, 4 strains of lactic acid bacteria (LAB), namely, Lactobacillus rhamnosus (LR5), Lactococ-cuslactis (SL3), Bifidobacterium breve (BR3), and Bifidobacterium lactis (BL3) were evaluated for their anti-C. difficile activity. Co-culture incubation of C. difficile (106 and 1010 CFU/ml) with each strain of LAB indicated that SL3 possessed the highest antimicrobial activity over a 24-hr period. The cell-free supernatants of the 4 LAB strains exhibited MIC50 values between 0.424 mg/ml (SL3) and 1.318 (BR3) mg/ml. These results may provide a basis for alternative therapies for the treatment of C. difficile-associated gut disorders.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aslam, S., Hamill, R.J. and Musher, D.M. (2005) Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis.., 5, 549–557.
Nelson, R. (2007) Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev.., 18, CD004610.
Bartlett, J.G. (2010) Clostridium difficile: progress and challenges. Ann. N. Y.Acad. Sci.., 1213, 62–69.
Ohl, M.E., Stevermer, J.J., Meadows, S., Tribuna, J. and Chek, K. (2005) What are effective therapies for Clostridium difficile-associated diarrhea? J. Fam. Pract., 54, 176–178.
Dethlefsen, L., Huse, S., Sogin, M.L. and Relman, D.A. (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol.., 6, e280.
Kang, B.S., Seo, J.G., Lee, G.S., Kim, J.H., Kim, S.Y., Han, Y.W., Kang, H., Kim, H.O., Rhee, J.H., Kang, B.S., Seo, J.G., Lee, G.S., Kim, J.H., Kim, S.Y., Han, Y.W., Kang, H., Kim, H.O., Rhee, J.H., Chung, M.J. and Park, YM. (2009) Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J. Microbiol.., 47, 101–109.
Forestier, C., De Champs, C., Vatoux, C. and Joly, B. (2001) Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res. Microbiol.., 152, 167–173.
Guarner, F. and Schaafsma, G.J. (1998) Probiotics. Int. J. Food Microbiol.., 39, 237–238.
Jin, L.Z., Ho, YW. Abdullah, N., All, M.A. and Jalaludin, S. (1996) Antagonistic effects of intestinal Lactobacillus isolates on pathogens of chicken. Lett. Appl. Microbiol.., 23, 67–71.
Aroutcheva, A., Gariti, D., Simon, M., Shott, S., Faro, J., Simoes, J.A., Gurguis, A. and Faro, S. (2001) Defense factors of vaginal lactobacilli. Am. J. Obstet. Gynecol.., 185, 375–379.
Surawicz, CM., McFarland, L.V., Greenberg, R.N., Rubin, M., Fekety, R., Mulligan, M.E., Garcia, R.J., Brandmarker, S., Bowen, K., Borjal, D. and Elmer, GW. (2000) The search for a better treatment for recurrent Clostridium difcile disease: use of high-dose vancomycin combined with Saccharomyces bou-lardii. Clin. Infect. Dis.., 31, 1012–1017.
McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Fekety, R., Elmer, G.W., Moyer, K.A., Melcher, S.A., Bowen, K.E., Cox, J.L., Noorani, Z., Harrington, G., Rubin, M. and Green-wald, D. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difcile disease. JAMA., 271, 1913–1918.
Pochapin, M. (2000) The effect of probiotics on Clostridium difcile diarrhea. Am. J. Gastroenterol.., 95, S11-S13.
Wullt, M., Hagslatt, M.L. and Odenholt, I. (2003) Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difcile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis.., 35, 365–367.
Lawrence, S.J., Korzenik, J.R. and Mundy, L.M. (2005) Probiotics for recurrent Clostridium difcile disease. J. Med. Microbiol.., 54, 905–906.
Guandalini, S. (2006) Probiotics for children: use in diarrhea. J. Clin. Gastroenterol.., 40, 244–248.
Katz, J.A. (2006) Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J. Clin. Gastroenterol.., 40, 249–255.
Fooks, L.J., Fuller, R. and Gibson, GR. (1999) Prebiotics, probiotics and human gut microbiology. Int. Dairy J.., 9, 53–61.
Cha, B.K., Jung, S.M., Choi, C.H., Song, I.D., Lee, H.W., Kim, H.J., Hyuk, J., Chang, S.K., Kim, K., Chung, W.S. and Seo, J.G. (2012) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J. Clin. Gastroenterol.., 46, 220–227.
Clinical and Laboratory Standards Institute. (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (7th ed.), Clinical and Laboratory Standards Institute, Wayne, PA., pp. 1–49.
Folkers, B.L., Schuring, C., Essmann, M. and Larsen, B. (2010) Quantitative real time PCR detection of Clostridium difficile growth inhibition by probiotic bacteria. N. Am. J. Med. Scl.., 2, 5–10.
Trejo, F.M., Perez, PR and De Antoni, G.L. (2010) Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro. Antonie van Leeuwenhoek.., 98, 19–29.
Gonzalez, L., Sandoval, H., Sacristan, N., Castro, J.M., Fresno, J.M. and Tornadijo, M.E. (2007) Identification of lactic acid bacteria isolated from Genestoso cheese throughout ripening and study of their antimicrobial activity. Food Control., 18, 716–722.
Bartoloni, A., Mantella, A., Goldstein, B.P., Dei, R., Bene-detti, M., Sbaragli, S. and Paradisi, F. (2004) In-vitro activity of nisin against clinical isolates of Clostridium difficile. J. Chemother.., 16, 119–121.
Kojic, M., Svicevic, J., Banina, A. and Topisirovic, L. (1991) Bacteriocin-producing strain of Lactococcus lactis subsp. diacitilactis S50. Appl. Environ. Microbiol.., 57, 1835–1837.
Kozak, W., Bardowski, J. and Dobrzansky, W.T. (1978) Lac-tostrepcins-acid bacteriocin produced by lactic streptococci. J. Dairy Res.., 45, 247–257.
De Vuyst, L. (1994) Nisin production variability between natural Lactococcus lactis subsp. Lactis strains. Biotechnol. Lett.., 16, 287–292.
Mulligan, M.E., Rolfe, R.D., Finegold, S.M. and George, W.L. (1979) Contamination of a hospital environment by Clostridium difficile. Curr Microbiol.., 3, 173–175.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Lee, JS., Chung, MJ. & Seo, JG. In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile. Toxicol Res. 29, 99–106 (2013). https://doi.org/10.5487/TR.2013.29.2.099
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2013.29.2.099